Generic placeholder image

Mini-Reviews in Medicinal Chemistry

Editor-in-Chief

ISSN (Print): 1389-5575
ISSN (Online): 1875-5607

Review Article

Bioactive Furanyl- or Thienyl-Substituted Nucleobases, Nucleosides and Their Analogues

Author(s): Tomasz Ostrowski*

Volume 23, Issue 5, 2023

Published on: 23 September, 2022

Page: [633 - 650] Pages: 18

DOI: 10.2174/1389557522666220812125205

Abstract

Five-membered heterocycles, including furan and thiophene, play a prominent role in drug design as structural units of bioactive molecules. This review is intended to demonstrate the importance of the furan-2-yl, furan-3-yl, thien-2-yl and thien-3-yl substituents in the medicinal chemistry of purine and pyrimidine nucleobases, nucleosides and selected analogues. Data presented in the article are limited to compounds containing heteroaromatic ring connected through a bond and not fused to other systems. The impact of bioisosteric replacement of aryl substituents with heteroaryl ones on activities was assessed by comparison of the title compounds with their aryl counterparts. A total of 135 heteroaryl-substituted and 35 aryl-substituted derivatives are mentioned in the text and shown in the figures. The following classes of compounds are included in the article: (i) 5-heteroaryl-2’-deoxyuridines and related compounds; (ii) 8-heteroaryl- 2,9-disubstituted adenine derivatives; (iii) O6-(heteroarylmethyl)guanines; (iv) 6-heteroaryl tricyclic guanine analogues; (v) 6-heteroaryl-9-benzylpurines and analogous compounds; (vi) N4- furfurylcytosine, N6-furfuryladenine, their derivatives and analogues; (vii) 6-heteroaryl purine and 7- deazapurine ribonucleosides; (viii) 7-heteroaryl-7-deazaadenosines, their derivatives and analogues; (ix) 4-heteroaryl fused 7-deazapurine nucleosides. In most cases various modifications of the lead compound structure performed in order to obtain the most favorable activity and selectivity are briefly discussed. The reviewed structure-activity relationship studies exemplify the search for compounds with optimized antiviral, antitumor, antimycobacterial or antiparkinsonian action.

Keywords: Nucleoside analogue, heteroaryl substituent, structure-activity relationship, antiviral activity, cytostatic activity, antimycobacterial activity, adenosine receptor antagonist.

« Previous
Graphical Abstract

[1]
Wigerinck, P.; Pannecouque, C.; Snoeck, R.; Claes, P.; De Clercq, E.; Herdewijn, P. 5-(5-Bromothien-2-yl)-2′-deoxyuridine and 5-(5-chlorothien-2-yl)-2′-deoxyuridine are equipotent to (E)-5-(2-bromovinyl)-2′-deoxyuridine in the inhibition of herpes simplex virus type I replication. J. Med. Chem., 1991, 34(8), 2383-2389.
[http://dx.doi.org/10.1021/jm00112a011] [PMID: 1652017]
[2]
Wigerinck, P.; Kerremans, L.; Claes, P.; Snoeck, R.; Maudgal, P.; De Clercq, E.; Herdewijn, P. Synthesis and antiviral activity of 5-thien-2-yl-2′-deoxyuridine analogues. J. Med. Chem., 1993, 36(5), 538-543.
[http://dx.doi.org/10.1021/jm00057a003] [PMID: 8388474]
[3]
Luyten, I.; Jie, L.; Van Aerschot, A.; Pannecouque, C.; Wigerinck, P.; Rozenski, J.; Hendrix, C.; Wang, C.; Wiebe, L.; Balzarini, J.; De Clercq, E.; Herdewijn, P. 2′-Deoxyuridines with a 5-heteroaromatic substituent: Synthesis and biological evaluation. Antivir. Chem. Chemother., 1995, 6(4), 262-270.
[http://dx.doi.org/10.1177/095632029500600409]
[4]
Liu, J.; Van Aerschot, A.; Luyten, I.; Wigerinck, P.; Pannecouque, C.; Balzarini, J.; De Clercq, E.; Herdewijn, P. Synthesis and antiviral activities of some new 5-heteroaromatic substituted derivatives of 2′-deoxyuridine. Nucleosides Nucleotides Nucleic Acids, 1995, 14(3), 525-528.
[http://dx.doi.org/10.1080/15257779508012418]
[5]
Andrei, G.; Snoeck, R.; Goubau, P.; Desmyter, J.; De Clercq, E. Comparative activity of various compounds against clinical strains of herpes simplex virus. Eur. J. Clin. Microbiol. Infect. Dis., 1992, 11(2), 143-151.
[http://dx.doi.org/10.1007/BF01967066] [PMID: 1327785]
[6]
Andrei, G.; Snoeck, R.; Reymen, D.; Liesnard, C.; Goubau, P.; Desmyter, J.; De Clercq, E. Comparative activity of selected antiviral compounds against clinical isolates of varicella-zoster virus. Eur. J. Clin. Microbiol. Infect. Dis., 1995, 14(4), 318-329.
[http://dx.doi.org/10.1007/BF02116525] [PMID: 7649195]
[7]
Bohman, C.; Balzarini, J.; Wigerinck, P.; Van Aerschot, A.; Herdewijn, P.; De Clercq, E. Mechanism of cytostatic action of novel 5-(thien-2-yl)- and 5-(furan-2-yl)-substituted pyrimidine nucleoside analogues against tumor cells transfected by the thymidine kinase gene of herpes simplex virus. J. Biol. Chem., 1994, 269(11), 8036-8043.
[http://dx.doi.org/10.1016/S0021-9258(17)37156-9] [PMID: 8132526]
[8]
Herdewijn, P.A.M.M. 5-Substituted-2′-deoxyuridines as anti-HSV-1 agents: Synthesis and structure activity relationship. Antivir. Chem. Chemother., 1994, 5(3), 131-146.
[http://dx.doi.org/10.1177/095632029400500301]
[9]
Wellmar, U.; Hornfeldt, A.-B.; Gronowitz, S.; Johansson, N.G. Synthesis of various 5-(3-substituted phenyl)-2′-deoxyuridines. Chem. Heterocycl. Compd., 1996, 32, 1312-1318.
[http://dx.doi.org/10.1007/BF01169963]
[10]
Wen, Z.; Suzol, S.H.; Peng, J.; Liang, Y.; Snoeck, R.; Andrei, G.; Liekens, S.; Wnuk, S.F. Antiviral and cytostatic evaluation of 5-(1-halo-2-sulfonylvinyl)- and 5-(2-furyl)uracil nucleosides. Arch. Pharm. (Weinheim), 2017, 350(3-4), e1700023.
[http://dx.doi.org/10.1002/ardp.201700023] [PMID: 28304114]
[11]
Ostrowski, T.; Wroblowski, B.; Busson, R.; Rozenski, J.; De Clercq, E.; Bennett, M.S.; Champness, J.N.; Summers, W.C.; Sanderson, M.R.; Herdewijn, P. 5-Substituted pyrimidines with a 1,5-anhydro-2, 3-dideoxy-D-arabino-hexitol moiety at N-1: Synthesis, antiviral activity, conformational analysis, and interaction with viral thymidine kinase. J. Med. Chem., 1998, 41(22), 4343-4353.
[http://dx.doi.org/10.1021/jm980287z] [PMID: 9784109]
[12]
Zimmermann, S.C.; Sadler, J.M.; Andrei, G.; Snoeck, R.; Balzarini, J.; Seley-Radtke, K.L. Carbocyclic 5′-nor “reverse” fleximers. Design, synthesis, and preliminary biological activity. MedChemComm, 2011, 2(7), 650-654.
[http://dx.doi.org/10.1039/c1md00094b] [PMID: 24312722]
[13]
Zimmermann, S.C.; Sadler, J.M.; O’Daniel, P.I.; Kim, N.T.; Seley-Radtke, K.L. “Reverse” carbocyclic fleximers: Synthesis of a new class of adenosine deaminase inhibitors. Nucleot. Nucl., 2013, 32(3), 137-154.
[http://dx.doi.org/10.1080/15257770.2013.771187] [PMID: 23473101]
[14]
Persson, T.; Hornfeldt, A-B.; Gronowitz, S.; Johansson, N.G. Thienyl-substituted nucleosides and their triphosphates. Antivir. Chem. Chemother., 1994, 5(6), 395-402.
[http://dx.doi.org/10.1177/095632029400500607]
[15]
Haouz, A.; Vanheusden, V.; Munier-Lehmann, H.; Froeyen, M.; Herdewijn, P.; Van Calenbergh, S.; Delarue, M. Enzymatic and structural analysis of inhibitors designed against Mycobacterium tuberculosis thymidylate kinase. New insights into the phosphoryl transfer mechanism. J. Biol. Chem., 2003, 278(7), 4963-4971.
[http://dx.doi.org/10.1074/jbc.M209630200] [PMID: 12454011]
[16]
Vanheusden, V.; Van Rompaey, P.; Munier-Lehmann, H.; Pochet, S.; Herdewijn, P.; Van Calenbergh, S. Thymidine and thymidine-5′-O-monophosphate analogues as inhibitors of Mycobacterium tuberculosis thymidylate kinase. Bioorg. Med. Chem. Lett., 2003, 13(18), 3045-3048.
[http://dx.doi.org/10.1016/S0960-894X(03)00643-7] [PMID: 12941330]
[17]
Meščić, A.; Harej, A.; Klobučar, M.; Glavač, D.; Cetina, M.; Pavelić, S.K.; Raić-Malić, S. Discovery of new acid ceramidase-targeted acyclic 5-alkynyl and 5-heteroaryl uracil nucleosides. ACS Med. Chem. Lett., 2015, 6(11), 1150-1155.
[http://dx.doi.org/10.1021/acsmedchemlett.5b00298] [PMID: 26617970]
[18]
Gazivoda, T.; Raić-Malić, S.; Marjanović, M.; Kralj, M.; Pavelić, K.; Balzarini, J.; De Clercq, E.; Mintas, M. The novel C-5 aryl, alkenyl, and alkynyl substituted uracil derivatives of L-ascorbic acid: synthesis, cytostatic, and antiviral activity evaluations. Bioorg. Med. Chem., 2007, 15(2), 749-758.
[http://dx.doi.org/10.1016/j.bmc.2006.10.046] [PMID: 17092728]
[19]
Zhang, X.; Li, D.; Qin, J.; Xu, Y.; Ma, K. Synthesis of 4-thio-5-(2”-thienyl)uridine and cytotoxicity activity against colon cancer cells in vitro. RSC Advances, 2016, 6(74), 70099-70105.
[http://dx.doi.org/10.1039/C6RA14356C]
[20]
Pesnot, T.; Jørgensen, R.; Palcic, M.M.; Wagner, G.K. Structural and mechanistic basis for a new mode of glycosyltransferase inhibition. Nat. Chem. Biol., 2010, 6(5), 321-323.
[http://dx.doi.org/10.1038/nchembio.343] [PMID: 20364127]
[21]
Descroix, K.; Pesnot, T.; Yoshimura, Y.; Gehrke, S.S.; Wakarchuk, W.; Palcic, M.M.; Wagner, G.K. Inhibition of galactosyltransferases by a novel class of donor analogues. J. Med. Chem., 2012, 55(5), 2015-2024.
[http://dx.doi.org/10.1021/jm201154p] [PMID: 22356319]
[22]
Jiang, J.; Kanabar, V.; Padilla, B.; Man, F.; Pitchford, S.C.; Page, C.P.; Wagner, G.K. Uncharged nucleoside inhibitors of β-1,4-galactosyltransferase with activity in cells. Chem. Commun. (Camb.), 2016, 52(20), 3955-3958.
[http://dx.doi.org/10.1039/C5CC09289B] [PMID: 26882174]
[23]
Wagner, G.K.; Pesnot, T.; Palcic, M.M.; Jørgensen, R. Novel UDP-GalNAc derivative structures provide insight into the donor specificity of human blood group glycosyltransferase. J. Biol. Chem., 2015, 290(52), 31162-31172.
[http://dx.doi.org/10.1074/jbc.M115.681262] [PMID: 26527682]
[24]
Jørgensen, R.; Pesnot, T.; Lee, H.J.; Palcic, M.M.; Wagner, G.K. Base-modified donor analogues reveal novel dynamic features of a glycosyltransferase. J. Biol. Chem., 2013, 288(36), 26201-26208.
[http://dx.doi.org/10.1074/jbc.M113.465963] [PMID: 23836908]
[25]
Descroix, K.; Wagner, G.K. The first C-glycosidic analogue of a novel galactosyltransferase inhibitor. Org. Biomol. Chem., 2011, 9(6), 1855-1863.
[http://dx.doi.org/10.1039/c0ob00630k] [PMID: 21267505]
[26]
Van Poecke, S.; Barrett, M.O.; Santhosh Kumar, T.; Sinnaeve, D.; Martins, J.C.; Jacobson, K.A.; Kendall Harden, T.; Van Calenbergh, S. Synthesis and P2Y2 receptor agonist activities of uridine 5′-phosphonate analogues. Bioorg. Med. Chem., 2012, 20(7), 2304-2315.
[http://dx.doi.org/10.1016/j.bmc.2012.02.012] [PMID: 22386981]
[27]
Cristalli, G.; Lambertucci, C.; Marucci, G.; Volpini, R.; Dal Ben, D. A2A adenosine receptor and its modulators: Overview on a druggable GPCR and on structure-activity relationship analysis and binding requirements of agonists and antagonists. Curr. Pharm. Des., 2008, 14(15), 1525-1552.
[http://dx.doi.org/10.2174/138161208784480081] [PMID: 18537675]
[28]
Clementina, M.; Giuseppe, S. A2A receptor ligands: Past, present and future trends. Curr. Top. Med. Chem., 2010, 10(9), 902-922.
[http://dx.doi.org/10.2174/156802610791268765] [PMID: 20370660]
[29]
Pinna, A.; Volpini, R.; Cristalli, G.; Morelli, M. New adenosine A2A receptor antagonists: Actions on Parkinson’s disease models. Eur. J. Pharmacol., 2005, 512(2-3), 157-164.
[http://dx.doi.org/10.1016/j.ejphar.2005.01.057] [PMID: 15840400]
[30]
Volpini, R.; Dal Ben, D.; Lambertucci, C.; Marucci, G.; Mishra, R.C.; Ramadori, A.T.; Klotz, K.-N.; Trincavelli, M.L.; Martini, C.; Cristalli, G. Adenosine A2A receptor antagonists: new 8-substituted 9-ethyladenines as tools for in vivo rat models of Parkinson’s disease. ChemMedChem, 2009, 4(6), 1010-1019.
[http://dx.doi.org/10.1002/cmdc.200800434] [PMID: 19343763]
[31]
Lambertucci, C.; Buccioni, M.; Dal Ben, D.; Kachler, S.; Marucci, G.; Spinaci, A.; Thomas, A.; Klotz, K.-N.; Volpini, R. New substituted 9-propyladenine derivatives as A2A adenosine receptor antagonists. MedChemComm, 2015, 6(5), 963-970.
[http://dx.doi.org/10.1039/C5MD00034C]
[32]
Dal Ben, D.; Buccioni, M.; Lambertucci, C.; Thomas, A.; Klotz, K-N.; Federico, S.; Cacciari, B.; Spalluto, G.; Volpini, R. 8-(2-Furyl)adenine derivatives as A₂A adenosine receptor ligands. Eur. J. Med. Chem., 2013, 70, 525-535.
[http://dx.doi.org/10.1016/j.ejmech.2013.10.006] [PMID: 24189496]
[33]
Endo, K.; Deguchi, K.; Matsunaga, H.; Tomaya, K.; Yamada, K. 8-Substituted 2-alkynyl-N(9)-propargyladenines as A2A adenosine receptor antagonists. Bioorg. Med. Chem., 2014, 22(12), 3072-3082.
[http://dx.doi.org/10.1016/j.bmc.2014.04.041] [PMID: 24815000]
[34]
Federico, S.; Ciancetta, A.; Porta, N.; Redenti, S.; Pastorin, G.; Cacciari, B.; Klotz, K.N.; Moro, S.; Spalluto, G. 5,7-Disubstituted-[1,2,4]triazolo[1,5-a][1,3,5]triazines as pharmacological tools to explore the antagonist selectivity profiles toward adenosine receptors. Eur. J. Med. Chem., 2016, 108, 529-541.
[http://dx.doi.org/10.1016/j.ejmech.2015.12.019] [PMID: 26717203]
[35]
Müller, C.E.; Jacobson, K.A. Recent developments in adenosine receptor ligands and their potential as novel drugs. Biochim. Biophys. Acta, 2011, 1808(5), 1290-1308.
[http://dx.doi.org/10.1016/j.bbamem.2010.12.017] [PMID: 21185259]
[36]
Moro, S.; Gao, Z.-G.; Jacobson, K.A.; Spalluto, G. Progress in the pursuit of therapeutic adenosine receptor antagonists. Med. Res. Rev., 2006, 26(2), 131-159.
[http://dx.doi.org/10.1002/med.20048] [PMID: 16380972]
[37]
McElhinney, R.S.; Donnelly, D.J.; McCormick, J.E.; Kelly, J.; Watson, A.J.; Rafferty, J.A.; Elder, R.H.; Middleton, M.R.; Willington, M.A.; McMurry, T.B.H.; Margison, G.P. Inactivation of O6-alkylguanine-DNA alkyltransferase. 1. Novel O6-(hetarylmethyl)guanines having basic rings in the side chain. J. Med. Chem., 1998, 41(26), 5265-5271.
[http://dx.doi.org/10.1021/jm9708644] [PMID: 9857094]
[38]
McElhinney, R.S.; McMurry, T.B.H.; Margison, G.P. O6-alkylguanine-DNA alkyltransferase inactivation in cancer chemotherapy. Mini Rev. Med. Chem., 2003, 3(5), 471-485.
[http://dx.doi.org/10.2174/1389557033487980] [PMID: 12769698]
[39]
Khan, O.; Middleton, M.R. The therapeutic potential of O6-alkylguanine DNA alkyltransferase inhibitors. Expert Opin. Investig. Drugs, 2007, 16(10), 1573-1584.
[http://dx.doi.org/10.1517/13543784.16.10.1573] [PMID: 17922622]
[40]
Khan, O.A.; Ranson, M.; Michael, M.; Olver, I.; Levitt, N.C.; Mortimer, P.; Watson, A.J.; Margison, G.P.; Midgley, R.; Middleton, M.R. A phase II trial of lomeguatrib and temozolomide in metastatic colorectal cancer. Br. J. Cancer, 2008, 98(10), 1614-1618.
[http://dx.doi.org/10.1038/sj.bjc.6604366] [PMID: 18475294]
[41]
Watson, A.J.; Sabharwal, A.; Thorncroft, M.; McGown, G.; Kerr, R.; Bojanic, S.; Soonawalla, Z.; King, A.; Miller, A.; Waller, S.; Leung, H.; Margison, G.P.; Middleton, M.R. Tumor O(6)-methylguanine-DNA methyltransferase inactivation by oral lomeguatrib. Clin. Cancer Res., 2010, 16(2), 743-749.
[http://dx.doi.org/10.1158/1078-0432.CCR-09-1389] [PMID: 20068091]
[42]
Golankiewicz, B.; Ostrowski, T. Tricyclic nucleoside analogues as antiherpes agents. Antiviral Res., 2006, 71(2-3), 134-140.
[http://dx.doi.org/10.1016/j.antiviral.2006.05.004] [PMID: 16780965]
[43]
Ostrowski, T.; Golankiewicz, B.; De Clercq, E.; Andrei, G.; Snoeck, R. Synthesis and anti-VZV activity of 6-heteroaryl derivatives of tricyclic acyclovir and 9-[cis-1′2′-bis(hydroxymethyl)cycloprop-1′-yl]methylguanine analogues. Eur. J. Med. Chem., 2009, 44(8), 3313-3317.
[http://dx.doi.org/10.1016/j.ejmech.2009.03.005] [PMID: 19339082]
[44]
Amblard, F.; Fromentin, E.; Detorio, M.; Obikhod, A.; Rapp, K.L.; McBrayer, T.R.; Whitaker, T.; Coats, S.J.; Schinazi, R.F. Synthesis, antiviral activity, and stability of nucleoside analogs containing tricyclic bases. Eur. J. Med. Chem., 2009, 44(10), 3845-3851.
[http://dx.doi.org/10.1016/j.ejmech.2009.04.003] [PMID: 19433343]
[45]
Mohammed, A.F.; Andrei, G.; Hayallah, A.M.; Abdel-Moty, S.G.; Snoeck, R.; Simons, C. Synthesis and anti-HSV activity of tricyclic penciclovir and hydroxybutylguanine derivatives. Bioorg. Med. Chem., 2019, 27(6), 1023-1033.
[http://dx.doi.org/10.1016/j.bmc.2019.02.005] [PMID: 30738653]
[46]
Bakkestuen, A.K.; Gundersen, L-L.; Langli, G.; Liu, F.; Nolsøe, J.M.J. 9-Benzylpurines with inhibitory activity against Mycobacterium tuberculosis. Bioorg. Med. Chem. Lett., 2000, 10(11), 1207-1210.
[http://dx.doi.org/10.1016/S0960-894X(00)00188-8] [PMID: 10866382]
[47]
Gundersen, L-L.; Nissen-Meyer, J.; Spilsberg, B. Synthesis and antimycobacterial activity of 6-arylpurines: The requirements for the N-9 substituent in active antimycobacterial purines. J. Med. Chem., 2002, 45(6), 1383-1386.
[http://dx.doi.org/10.1021/jm0110284] [PMID: 11882008]
[48]
Bakkestuen, A.K.; Gundersen, L-L.; Utenova, B.T. Synthesis, biological activity, and SAR of antimycobacterial 9-aryl-, 9-arylsulfonyl-, and 9-benzyl-6-(2-furyl)purines. J. Med. Chem., 2005, 48(7), 2710-2723.
[http://dx.doi.org/10.1021/jm0408924] [PMID: 15801862]
[49]
Braendvang, M.; Gundersen, L-L. Selective anti-tubercular purines: Synthesis and chemotherapeutic properties of 6-aryl- and 6-heteroaryl-9-benzylpurines. Bioorg. Med. Chem., 2005, 13(23), 6360-6373.
[http://dx.doi.org/10.1016/j.bmc.2005.06.054] [PMID: 16081292]
[50]
Braendvang, M.; Gundersen, L-L. Synthesis, biological activity, and SAR of antimycobacterial 2- and 8-substituted 6-(2-furyl)-9-(p-methoxybenzyl)purines. Bioorg. Med. Chem., 2007, 15(22), 7144-7165.
[http://dx.doi.org/10.1016/j.bmc.2007.07.034] [PMID: 17804243]
[51]
Khoje, A.D.; Kulendrn, A.; Charnock, C.; Wan, B.; Franzblau, S.; Gundersen, L.-L. Synthesis of non-purine analogs of 6-aryl-9-benzylpurines, and their antimycobacterial activities. Compounds modified in the imidazole ring. Bioorg. Med. Chem., 2010, 18(20), 7274-7282.
[http://dx.doi.org/10.1016/j.bmc.2010.08.016] [PMID: 20833056]
[52]
Khoje, A.D.; Charnock, C.; Wan, B.; Franzblau, S.; Gundersen, L.-L. Synthesis and antimycobacterial activities of non-purine analogs of 6-aryl-9-benzylpurines: Imidazopyridines, pyrrolopyridines, benzimidazoles, and indoles. Bioorg. Med. Chem., 2011, 19(11), 3483-3491.
[http://dx.doi.org/10.1016/j.bmc.2011.04.023] [PMID: 21546254]
[53]
Braendvang, M.; Charnock, C.; Gundersen, L.-L. Synthesis and antimycobacterial activity of 5-formylaminopyrimidines; analogs of antibacterial purines. Bioorg. Med. Chem. Lett., 2009, 19(12), 3297-3299.
[http://dx.doi.org/10.1016/j.bmcl.2009.04.082] [PMID: 19427200]
[54]
Gillespie, R.J.; Cliffe, I.A.; Dawson, C.E.; Dourish, C.T.; Gaur, S.; Jordan, A.M.; Knight, A.R.; Lerpiniere, J.; Misra, A.; Pratt, R.M.; Roffey, J.; Stratton, G.C.; Upton, R.; Weiss, S.M.; Williamson, D.S. Antagonists of the human adenosine A2A receptor. Part 3: Design and synthesis of pyrazolo[3,4-d]pyrimidines, pyrrolo[2,3-d]pyrimidines and 6-arylpurines. Bioorg. Med. Chem. Lett., 2008, 18(9), 2924-2929.
[http://dx.doi.org/10.1016/j.bmcl.2008.03.072] [PMID: 18411049]
[55]
Kiselgof, E.; Tulshian, D.B.; Arik, L.; Zhang, H.; Fawzi, A. 6-(2-Furanyl)-9H-purin-2-amine derivatives as A2A adenosine antagonists. Bioorg. Med. Chem. Lett., 2005, 15(8), 2119-2122.
[http://dx.doi.org/10.1016/j.bmcl.2005.02.031] [PMID: 15808481]
[56]
Gillespie, R.J.; Bamford, S.J.; Botting, R.; Comer, M.; Denny, S.; Gaur, S.; Griffin, M.; Jordan, A.M.; Knight, A.R.; Lerpiniere, J.; Leonardi, S.; Lightowler, S.; McAteer, S.; Merrett, A.; Misra, A.; Padfield, A.; Reece, M.; Saadi, M.; Selwood, D.L.; Stratton, G.C.; Surry, D.; Todd, R.; Tong, X.; Ruston, V.; Upton, R.; Weiss, S.M. Antagonists of the human A(2A) adenosine receptor. 4. Design, synthesis, and preclinical evaluation of 7-aryltriazolo[4,5-d]pyrimidines. J. Med. Chem., 2009, 52(1), 33-47.
[http://dx.doi.org/10.1021/jm800961g] [PMID: 19072055]
[57]
Pinna, A. Adenosine A2A receptor antagonists in Parkinson’s disease: Progress in clinical trials from the newly approved istradefylline to drugs in early development and those already discontinued. CNS Drugs, 2014, 28(5), 455-474.
[http://dx.doi.org/10.1007/s40263-014-0161-7] [PMID: 24687255]
[58]
Willingham, S.B.; Ho, P.Y.; Hotson, A.; Hill, C.; Piccione, E.C.; Hsieh, J.; Liu, L.; Buggy, J.J.; McCaffery, I.; Miller, R.A. A2AR antagonism with CPI-444 induces antitumor responses and augments efficacy to anti-PD-(L)1 and anti-CTLA-4 in preclinical models. Cancer Immunol. Res., 2018, 6(10), 1136-1149.
[http://dx.doi.org/10.1158/2326-6066.CIR-18-0056] [PMID: 30131376]
[59]
Huck, B.R.; Kötzner, L.; Urbahns, K. Small molecules drive big improvements in immuno-oncology therapies. Angew. Chem. Int. Ed. Engl., 2018, 57(16), 4412-4428.
[http://dx.doi.org/10.1002/anie.201707816] [PMID: 28971564]
[60]
Plitta, B.; Adamska, E.; Giel-Pietraszuk, M.; Fedoruk-Wyszomirska, A.; Naskręt-Barciszewska, M.; Markiewicz, W.T.; Barciszewski, J. New cytosine derivatives as inhibitors of DNA methylation. Eur. J. Med. Chem., 2012, 55, 243-254.
[http://dx.doi.org/10.1016/j.ejmech.2012.07.024] [PMID: 22854677]
[61]
Voller, J.; Beres, T.; Zatloukal, M.; Dzubak, P.; Hajduch, M.; Dolezal, K.; Schmulling, T.; Strnad, M. Anti-cancer activities of cytokinin ribosides. Phytochem. Rev., 2019, 18(4), 1101-1113.
[http://dx.doi.org/10.1007/s11101-019-09620-4]
[62]
Voller, J.; Zatloukal, M.; Lenobel, R.; Dolezal, K.; Béres, T.; Krystof, V.; Spíchal, L.; Niemann, P.; Dzubák, P.; Hajdúch, M.; Strnad, M. Anticancer activity of natural cytokinins: A structure-activity relationship study. Phytochemistry, 2010, 71(11-12), 1350-1359.
[http://dx.doi.org/10.1016/j.phytochem.2010.04.018] [PMID: 20553699]
[63]
Cappellacci, L.; Franchetti, P.; Vita, P.; Petrelli, R.; Lavecchia, A.; Jayaram, H.N.; Saiko, P.; Graser, G.; Szekeres, T.; Grifantini, M. Ribose-modified purine nucleosides as ribonucleotide reductase inhibitors. Synthesis, antitumor activity, and molecular modeling of N6-substituted 3′-C-methyladenosine derivatives. J. Med. Chem., 2008, 51(14), 4260-4269.
[http://dx.doi.org/10.1021/jm800205c] [PMID: 18588281]
[64]
Gao, Z-G.; Blaustein, J.B.; Gross, A.S.; Melman, N.; Jacobson, K.A.N. N6-Substituted adenosine derivatives: Selectivity, efficacy, and species differences at A3 adenosine receptors. Biochem. Pharmacol., 2003, 65(10), 1675-1684.
[http://dx.doi.org/10.1016/S0006-2952(03)00153-9] [PMID: 12754103]
[65]
Amiable, C.; Pochet, S.; Padilla, A.; Labesse, G.; Kaminski, P.A.N.N. (6)-substituted AMPs inhibit mammalian deoxynucleotide N-hydrolase DNPH1. PLoS One, 2013, 8(11), e80755.
[http://dx.doi.org/10.1371/journal.pone.0080755] [PMID: 24260472]
[66]
Orlicka-Płocka, M.; Fedoruk-Wyszomirska, A.; Gurda-Woźna, D.; Pawelczak, P.; Krawczyk, P.; Giel-Pietraszuk, M.; Framski, G.; Ostrowski, T.; Wyszko, E. Implications of oxidative stress in glioblastoma multiforme following treatment with purine derivatives. Antioxidants, 2021, 10(6), 950.
[http://dx.doi.org/10.3390/antiox10060950] [PMID: 34204594]
[67]
Choi, B-H.; Kim, W.; Wang, Q.C.; Kim, D-C.; Tan, S.N.; Yong, J.W.H.; Kim, K-T.; Yoon, H.S. Kinetin riboside preferentially induces apoptosis by modulating Bcl-2 family proteins and caspase-3 in cancer cells. Cancer Lett., 2008, 261(1), 37-45.
[http://dx.doi.org/10.1016/j.canlet.2007.11.014] [PMID: 18162289]
[68]
Cabello, C.M.; Bair, W.B., III; Ley, S.; Lamore, S.D.; Azimian, S.; Wondrak, G.T. The experimental chemotherapeutic N6-furfuryladenosine (kinetin-riboside) induces rapid ATP depletion, genotoxic stress, and CDKN1A(p21) upregulation in human cancer cell lines. Biochem. Pharmacol., 2009, 77(7), 1125-1138.
[http://dx.doi.org/10.1016/j.bcp.2008.12.002] [PMID: 19186174]
[69]
Dudzik, P.; Dulińska-Litewka, J.; Wyszko, E.; Jędrychowska, P.; Opałka, M.; Barciszewski, J.; Laidler, P. Effects of kinetin riboside on proliferation and proapoptotic activities in human normal and cancer cell lines. J. Cell. Biochem., 2011, 112(8), 2115-2124.
[http://dx.doi.org/10.1002/jcb.23132] [PMID: 21465535]
[70]
Drenichev, M.S.; Oslovsky, V.E.; Sun, L.; Tijsma, A.; Kurochkin, N.N.; Tararov, V.I.; Chizhov, A.O.; Neyts, J.; Pannecouque, C.; Leyssen, P.; Mikhailov, S.N. Modification of the length and structure of the linker of N(6)-benzyladenosine modulates its selective antiviral activity against enterovirus 71. Eur. J. Med. Chem., 2016, 111, 84-94.
[http://dx.doi.org/10.1016/j.ejmech.2016.01.036] [PMID: 26854380]
[71]
Oslovsky, V.E.; Drenichev, M.S.; Sun, L.; Kurochkin, N.N.; Kunetsky, V.E.; Mirabelli, C.; Neyts, J.; Leyssen, P.; Mikhailov, S.N. Fluorination of naturally occurring N6-benzyladenosine remarkably increased its antiviral activity and selectivity. Molecules, 2017, 22(7), 1219.
[http://dx.doi.org/10.3390/molecules22071219] [PMID: 28726764]
[72]
Vistoli, G.; Brizzolari, A.; Faioni, E.; Razzari, C.; Santaniello, E. Naturally occurring N(6)-substituted adenosines (cytokinin ribosides) are in vitro inhibitors of platelet aggregation: An in silico evaluation of their interaction with the P2Y(12) receptor. Bioorg. Med. Chem. Lett., 2014, 24(24), 5652-5655.
[http://dx.doi.org/10.1016/j.bmcl.2014.10.080] [PMID: 25467153]
[73]
Barciszewski, J.; Massino, F.; Clark, B.F.C. Kinetin - a multiactive molecule. Int. J. Biol. Macromol., 2007, 40(3), 182-192.
[http://dx.doi.org/10.1016/j.ijbiomac.2006.06.024] [PMID: 16899291]
[74]
Duszka, K.; Clark, B.F.C.; Massino, F.; Barciszewski, J. Biological activities of kinetin. In: Herbal Drugs: Ethnomedicine to Modern Medicine; Ramawat, K.G., Ed.; Springer-Verlag: Berlin, Heidelberg, 2009; pp. 369-380.
[http://dx.doi.org/10.1007/978-3-540-79116-4_20]
[75]
Hönig, M.; Plíhalová, L.; Husičková, A.; Nisler, J.; Doležal, K. Role of cytokinins in senescence, antioxidant defence and photosynthesis. Int. J. Mol. Sci., 2018, 19(12), 4045.
[http://dx.doi.org/10.3390/ijms19124045] [PMID: 30558142]
[76]
Kadlecová, A.; Maková, B.; Artal-Sanz, M.; Strnad, M.; Voller, J. The plant hormone kinetin in disease therapy and healthy aging. Ageing Res. Rev., 2019, 55, 100958.
[http://dx.doi.org/10.1016/j.arr.2019.100958] [PMID: 31479763]
[77]
Mik, V.; Szüčová, L.; Smehilová, M.; Zatloukal, M.; Doležal, K.; Nisler, J.; Grúz, J.; Galuszka, P.; Strnad, M.; Spíchal, L. N9-substituted derivatives of kinetin: Effective anti-senescence agents. Phytochemistry, 2011, 72(8), 821-831.
[http://dx.doi.org/10.1016/j.phytochem.2011.02.002] [PMID: 21354583]
[78]
Hönig, M.; Plíhalová, L.; Spíchal, L.; Grúz, J.; Kadlecová, A.; Voller, J.; Svobodová, A.R.; Vostálová, J.; Ulrichová, J.; Doležal, K.; Strnad, M. New cytokinin derivatives possess UVA and UVB photoprotective effect on human skin cells and prevent oxidative stress. Eur. J. Med. Chem., 2018, 150, 946-957.
[http://dx.doi.org/10.1016/j.ejmech.2018.03.043] [PMID: 29604584]
[79]
Maková, B.; Mik, V.; Lišková, B.; Gonzalez, G.; Vítek, D.; Medvedíková, M.; Monfort, B.; Ručilová, V.; Kadlecová, A.; Khirsariya, P.; Gándara Barreiro, Z.; Havlíček, L.; Zatloukal, M.; Soural, M.; Paruch, K.; D’Autréaux, B.; Hajdúch, M.; Strnad, M.; Voller, J. Cytoprotective activities of kinetin purine isosteres. Bioorg. Med. Chem., 2021, 33, 115993.
[http://dx.doi.org/10.1016/j.bmc.2021.115993] [PMID: 33497938]
[80]
Oshchepkov, M.S.; Kalistratova, A.V.; Savelieva, E.M.; Romanov, G.A.; Bystrova, N.A.; Kochetkov, K.A. Natural and synthetic cytokinins and their applications in biotechnology, agrochemistry and medicine. Russ. Chem. Rev., 2020, 89(8), 787-810.
[http://dx.doi.org/10.1070/RCR4921]
[81]
Hocek, M.; Holý, A.; Votruba, I.; Dvoráková, H. Synthesis and cytostatic activity of substituted 6-phenylpurine bases and nucleosides: Application of the Suzuki-Miyaura cross-coupling reactions of 6-chloropurine derivatives with phenylboronic acids. J. Med. Chem., 2000, 43(9), 1817-1825.
[http://dx.doi.org/10.1021/jm991167+] [PMID: 10794698]
[82]
Hocek, M.; Holy, A.; Votruba, I.; Dvorakova, H. Cytostatic 6-arylpurine nucleosides III. Synthesis and structure-activity relationship study in cytostatic activity of 6-aryl-, 6-hetaryl- and 6-benzylpurine ribonucleosides. Collect. Czech. Chem. Commun., 2001, 66(3), 483-499.
[http://dx.doi.org/10.1135/cccc20010483]
[83]
Hocek, M.; Naus, P.; Pohl, R.; Votruba, I.; Furman, P.A.; Tharnish, P.M.; Otto, M.J. Cytostatic 6-arylpurine nucleosides. 6. SAR in anti-HCV and cytostatic activity of extended series of 6-hetarylpurine ribonucleosides. J. Med. Chem., 2005, 48(18), 5869-5873.
[http://dx.doi.org/10.1021/jm050335x] [PMID: 16134952]
[84]
Kimoto, M.; Moriyama, K.; Yokoyama, S.; Hirao, I. Cytostatic evaluations of nucleoside analogs related to unnatural base pairs for a genetic expansion system. Bioorg. Med. Chem. Lett., 2007, 17(20), 5582-5585.
[http://dx.doi.org/10.1016/j.bmcl.2007.07.088] [PMID: 17804231]
[85]
Hassan, A.E.A.; Abou-Elkhair, R.A.I.; Riordan, J.M.; Allan, P.W.; Parker, W.B.; Khare, R.; Waud, W.R.; Montgomery, J.A.; Secrist, J.A., III Synthesis and evaluation of the substrate activity of C-6 substituted purine ribosides with E. coli purine nucleoside phosphorylase: Palladium mediated cross-coupling of organozinc halides with 6-chloropurine nucleosides. Eur. J. Med. Chem., 2012, 47(1), 167-174.
[http://dx.doi.org/10.1016/j.ejmech.2011.10.039] [PMID: 22112758]
[86]
Hocek, M.; Silhar, P.; Pohl, R. Cytostatic and antiviral 6-arylpurine ribonucleosides VIII. Synthesis and evaluation of 6-substituted purine 3′-deoxyribonucleosides. Collect. Czech. Chem. Commun., 2006, 71(10), 1484-1496.
[http://dx.doi.org/10.1135/cccc20061484]
[87]
Naus, P.; Kuchar, M.; Hocek, M. Cytostatic and antiviral 6-arylpurine ribonucleosides IX. Synthesis and evaluation of 6-substituted 3-deazapurine ribonucleosides. Collect. Czech. Chem. Commun., 2008, 73(5), 665-678.
[http://dx.doi.org/10.1135/cccc20080665]
[88]
Hocek, M.; Silhár, P.; Shih, I.H.; Mabery, E.; Mackman, R. Cytostatic and antiviral 6-arylpurine ribonucleosides. Part 7: Synthesis and evaluation of 6-substituted purine l-ribonucleosides. Bioorg. Med. Chem. Lett., 2006, 16(20), 5290-5293.
[http://dx.doi.org/10.1016/j.bmcl.2006.07.092] [PMID: 16905315]
[89]
Ding, Y.; Girardet, J-L.; Hong, Z.; Lai, V.C.H.; An, H.; Koh, Y-H.; Shaw, S.Z.; Zhong, W. Synthesis of 9-(2-β-C-methyl-β-d-ribofuranosyl)-6-substituted purine derivatives as inhibitors of HCV RNA replication. Bioorg. Med. Chem. Lett., 2005, 15(3), 709-713.
[http://dx.doi.org/10.1016/j.bmcl.2004.11.020] [PMID: 15664842]
[90]
Amiable, C.; Paoletti, J.; Haouz, A.; Padilla, A.; Labesse, G.; Kaminski, P-A.; Pochet, S. 6-(Hetero)Arylpurine nucleotides as inhibitors of the oncogenic target DNPH1: Synthesis, structural studies and cytotoxic activities. Eur. J. Med. Chem., 2014, 85, 418-437.
[http://dx.doi.org/10.1016/j.ejmech.2014.07.110] [PMID: 25108359]
[91]
Perlíková, P.; Hocek, M. Pyrrolo[2,3-d]pyrimidine (7-deazapurine) as a privileged scaffold in design of antitumor and antiviral nucleosides. Med. Res. Rev., 2017, 37(6), 1429-1460.
[http://dx.doi.org/10.1002/med.21465] [PMID: 28834581]
[92]
Naus, P.; Pohl, R.; Votruba, I.; Dzubák, P.; Hajdúch, M.; Ameral, R.; Birkus, G.; Wang, T.; Ray, A.S.; Mackman, R.; Cihlar, T.; Hocek, M. 6-(Het)aryl-7-deazapurine ribonucleosides as novel potent cytostatic agents. J. Med. Chem., 2010, 53(1), 460-470.
[http://dx.doi.org/10.1021/jm901428k] [PMID: 19929004]
[93]
Perlíková, P.; Pohl, R.; Votruba, I.; Shih, R.; Birkuš, G.; Cihlář, T.; Hocek, M. Phosphoramidate pronucleotides of cytostatic 6-aryl-7-deazapurine ribonucleosides. Bioorg. Med. Chem., 2011, 19(1), 229-242.
[http://dx.doi.org/10.1016/j.bmc.2010.11.029] [PMID: 21134754]
[94]
Perlikova, P.; Konecny, P.; Naus, P.; Snasel, J.; Votruba, I.; Dzubak, P.; Pichova, I.; Hajduch, M.; Hocek, M. 6-Alkyl-, 6-aryl- or 6-hetaryl-7-deazapurine ribonucleosides as inhibitors of human or MTB adenosine kinase and potential antimycobacterial agents. MedChemComm, 2013, 4(11), 1497-1500.
[http://dx.doi.org/10.1039/c3md00232b]
[95]
Malnuit, V.; Slavětínská, L.P.; Nauš, P.; Džubák, P.; Hajdúch, M.; Stolaříková, J.; Snášel, J.; Pichová, I.; Hocek, M. 2-Substituted 6-(het)aryl-7-deazapurine ribonucleosides: Synthesis, inhibition of adenosine kinases, and antimycobacterial activity. ChemMedChem, 2015, 10(6), 1079-1093.
[http://dx.doi.org/10.1002/cmdc.201500081] [PMID: 25882678]
[96]
Bourderioux, A.; Naus, P.; Perlíková, P.; Pohl, R.; Pichová, I.; Votruba, I.; Dzubák, P.; Konecný, P.; Hajdúch, M.; Stray, K.M.; Wang, T.; Ray, A.S.; Feng, J.Y.; Birkus, G.; Cihlar, T.; Hocek, M. Synthesis and significant cytostatic activity of 7-hetaryl-7-deazaadenosines. J. Med. Chem., 2011, 54(15), 5498-5507.
[http://dx.doi.org/10.1021/jm2005173] [PMID: 21711054]
[97]
Klecka, M.; Postova Slavetinska, L.; Tloust’ova, E.; Dzubak, P.; Hajduch, M.; Hocek, M. Synthesis and cytostatic activity of 7-arylsulfanyl-7-deazapurine bases and ribonucleosides. MedChemComm, 2015, 6(4), 576-580.
[http://dx.doi.org/10.1039/C4MD00492B]
[98]
Perlíková, P.; Rylová, G.; Nauš, P.; Elbert, T.; Tloušťová, E.; Bourderioux, A.; Slavětínská, L.P.; Motyka, K.; Doležal, D.; Znojek, P.; Nová, A.; Harvanová, M.; Džubák, P.; Šiller, M.; Hlaváč, J.; Hajdúch, M.; Hocek, M. 7-(2-Thienyl)-7-deazaadenosine (AB61), a new potent nucleoside cytostatic with a complex mode of action. Mol. Cancer Ther., 2016, 15(5), 922-937.
[http://dx.doi.org/10.1158/1535-7163.MCT-14-0933] [PMID: 26819331]
[99]
Nauš, P.; Perlíková, P.; Bourderioux, A.; Pohl, R.; Slavětínská, L.; Votruba, I.; Bahador, G.; Birkuš, G.; Cihlář, T.; Hocek, M. Sugar-modified derivatives of cytostatic 7-(het)aryl-7-deazaadenosines: 2′-C-methylribonucleosides, 2′-deoxy-2′-fluoroarabinonucleosides, arabinonucleosides and 2′-deoxyribonucleosides. Bioorg. Med. Chem., 2012, 20(17), 5202-5214.
[http://dx.doi.org/10.1016/j.bmc.2012.07.003] [PMID: 22877872]
[100]
Nauš, P.; Caletková, O.; Perlíková, P.; Poštová Slavětínská, L.; Tloušťová, E.; Hodek, J.; Weber, J.; Džubák, P.; Hajdúch, M.; Hocek, M. Synthesis and biological profiling of 6- or 7-(het)aryl-7-deazapurine 4′-C-methylribonucleosides. Bioorg. Med. Chem., 2015, 23(23), 7422-7438.
[http://dx.doi.org/10.1016/j.bmc.2015.10.040] [PMID: 26558518]
[101]
Snášel, J.; Nauš, P.; Dostál, J.; Hnízda, A.; Fanfrlík, J.; Brynda, J.; Bourderioux, A.; Dušek, M.; Dvořáková, H.; Stolaříková, J.; Zábranská, H.; Pohl, R.; Konečný, P.; Džubák, P.; Votruba, I.; Hajdúch, M.; Rezáčová, P.; Veverka, V.; Hocek, M.; Pichová, I. Structural basis for inhibition of mycobacterial and human adenosine kinase by 7-substituted 7-(Het)aryl-7-deazaadenine ribonucleosides. J. Med. Chem., 2014, 57(20), 8268-8279.
[http://dx.doi.org/10.1021/jm500497v] [PMID: 25259627]
[102]
Nauš, P.; Caletková, O.; Konečný, P.; Džubák, P.; Bogdanová, K.; Kolář, M.; Vrbková, J.; Slavětínská, L.; Tloušt’ová, E.; Perlíková, P.; Hajdúch, M.; Hocek, M. Synthesis, cytostatic, antimicrobial, and anti-HCV activity of 6-substituted 7-(het)aryl-7-deazapurine ribonucleosides. J. Med. Chem., 2014, 57(3), 1097-1110.
[http://dx.doi.org/10.1021/jm4018948] [PMID: 24397620]
[103]
Milisavljevic, N.; Konkolová, E.; Kozák, J.; Hodek, J.; Veselovská, L.; Sýkorová, V.; Čížek, K.; Pohl, R.; Eyer, L.; Svoboda, P.; Růžek, D.; Weber, J.; Nencka, R.; Bouřa, E.; Hocek, M. Antiviral activity of 7-substituted 7-deazapurine ribonucleosides, monophosphate prodrugs, and triphosphates against emerging RNA viruses. ACS Infect. Dis., 2021, 7(2), 471-478.
[http://dx.doi.org/10.1021/acsinfecdis.0c00829] [PMID: 33395259]
[104]
Tichý, M.; Pohl, R.; Xu, H.Y.; Chen, Y.-L.; Yokokawa, F.; Shi, P.-Y.; Hocek, M. Synthesis and antiviral activity of 4,6-disubstituted pyrimido[4,5-b]indole ribonucleosides. Bioorg. Med. Chem., 2012, 20(20), 6123-6133.
[http://dx.doi.org/10.1016/j.bmc.2012.08.021] [PMID: 22985963]
[105]
Tokarenko, A.; Lišková, B.; Smoleń, S.; Táborská, N.; Tichý, M.; Gurská, S.; Perlíková, P.; Frydrych, I.; Tloušt’ová, E.; Znojek, P.; Mertlíková-Kaiserová, H.; Poštová Slavětínská, L.; Pohl, R.; Klepetářová, B.; Khalid, N.U.A.; Wenren, Y.; Laposa, R.R.; Džubák, P.; Hajdúch, M.; Hocek, M. Synthesis and cytotoxic and antiviral profiling of pyrrolo- and furo-fused 7-deazapurine ribonucleosides. J. Med. Chem., 2018, 61(20), 9347-9359.
[http://dx.doi.org/10.1021/acs.jmedchem.8b01258] [PMID: 30281308]
[106]
Tichý, M.; Smoleń, S.; Tloušt’ová, E.; Pohl, R.; Oždian, T.; Hejtmánková, K.; Lišková, B.; Gurská, S.; Džubák, P.; Hajdúch, M.; Hocek, M. Synthesis and cytostatic and antiviral profiling of thieno-fused 7-deazapurine ribonucleosides. J. Med. Chem., 2017, 60(6), 2411-2424.
[http://dx.doi.org/10.1021/acs.jmedchem.6b01766] [PMID: 28221790]
[107]
Veselovská, L.; Kudlová, N.; Gurská, S.; Lišková, B.; Medvedíková, M.; Hodek, O.; Tloušťová, E.; Milisavljevic, N.; Tichý, M.; Perlíková, P.; Mertlíková-Kaiserová, H.; Trylčová, J.; Pohl, R.; Klepetářová, B.; Džubák, P.; Hajdúch, M.; Hocek, M. Synthesis and cytotoxic and antiviral activity profiling of all-four isomeric series of pyrido-fused 7-deazapurine ribonucleosides. Chemistry, 2020, 26(57), 13002-13015.
[http://dx.doi.org/10.1002/chem.202001124] [PMID: 32275109]

© 2025 Bentham Science Publishers | Privacy Policy
Request history8.2.27PHP Version616msRequest Duration28MBMemory UsageGET article/{article_id}/{param?}Route
  • warninglog[20:40:19] LOG.warning: Optional parameter $article_id declared before required parameter $request i...
  • warninglog[20:40:19] LOG.warning: Function strftime() is deprecated in /home/alphaeurekaselec/public_html/stor...
  • warninglog[20:40:19] LOG.warning: trim(): Passing null to parameter #1 ($string) of type string is deprecated ...
  • warninglog[20:40:19] LOG.warning: Function strftime() is deprecated in /home/alphaeurekaselec/public_html/stor...
  • Booting (104ms)time
  • Application (512ms)time
  • 1 x Application (83.14%)
    512ms
    1 x Booting (16.86%)
    104ms
    14 templates were rendered
    • articlearticle.blade.php#?blade
    • includes.article_top_bannerarticle_top_banner.blade.php#?blade
    • includes.article_referencearticle_reference.blade.php#?blade
    • export_citation_formexport_citation_form.blade.php#?blade
    • includes.article_bottom_bannerarticle_bottom_banner.blade.php#?blade
    • includes.inc_related_journalsinc_related_journals.blade.php#?blade
    • includes.inc_related_ebooksinc_related_ebooks.blade.php#?blade
    • includes.journal_rightmenujournal_rightmenu.blade.php#?blade
    • includes.journal_right_bannerjournal_right_banner.blade.php#?blade
    • layouts.appapp.blade.php#?blade
    • layouts._login_access_login_access.blade.php#?blade
    • layouts._header_header.blade.php#?blade
    • layouts._main_menu_main_menu.blade.php#?blade
    • layouts._footer_menu_footer_menu.blade.php#?blade
    uri
    GET article/{article_id}/{param?}
    middleware
    web, check_user_access
    controller
    App\Http\Controllers\ArticleController@GetArticleDetails
    namespace
    App\Http\Controllers
    where
    as
    article
    file
    app/Http/Controllers/ArticleController.php:1974-2510
    31 statements were executed, 4 of which were duplicates, 27 unique. Show only duplicated402ms
    • Connection Establishedalphaeurekaselec_live_10_06_2022UserAccessCheck.php#24
      Backtrace
      • 9. middleware::check_user_access:24
      • 10. vendor/laravel/framework/src/Illuminate/Pipeline/Pipeline.php:183
      • 11. vendor/laravel/framework/src/Illuminate/Routing/Middleware/SubstituteBindings.php:50
      • 12. vendor/laravel/framework/src/Illuminate/Pipeline/Pipeline.php:183
      • 13. vendor/laravel/framework/src/Illuminate/Foundation/Http/Middleware/VerifyCsrfToken.php:88
    • INSERT INTO visitor_ip_address (ip_address,visitor_agent,visitor_count, created_on,updated_on) VALUES ('316574772','',1,1740775219,1740775219) ON DUPLICATE KEY UPDATE visitor_count=visitor_count + 1, updated_on=1740775219
      1.67msalphaeurekaselec_live_10_06_2022UserAccessCheck.php#24
      Backtrace
      • 11. middleware::check_user_access:24
      • 12. vendor/laravel/framework/src/Illuminate/Pipeline/Pipeline.php:183
      • 13. vendor/laravel/framework/src/Illuminate/Routing/Middleware/SubstituteBindings.php:50
      • 14. vendor/laravel/framework/src/Illuminate/Pipeline/Pipeline.php:183
      • 15. vendor/laravel/framework/src/Illuminate/Foundation/Http/Middleware/VerifyCsrfToken.php:88
    • INSERT INTO visitor_ip_address_detail (ip_address,visitor_url,visitor_count, created_on,updated_on) VALUES ('316574772','/article/125449',1,1740775219,1740775219)
      250μsalphaeurekaselec_live_10_06_2022UserAccessCheck.php#27
      Backtrace
      • 11. middleware::check_user_access:27
      • 12. vendor/laravel/framework/src/Illuminate/Pipeline/Pipeline.php:183
      • 13. vendor/laravel/framework/src/Illuminate/Routing/Middleware/SubstituteBindings.php:50
      • 14. vendor/laravel/framework/src/Illuminate/Pipeline/Pipeline.php:183
      • 15. vendor/laravel/framework/src/Illuminate/Foundation/Http/Middleware/VerifyCsrfToken.php:88
    • (select `user_id`, `to_ip`, `from_ip` from (select user_id, to_ip, from_ip FROM user_access_journal_volume_trail WHERE to_ip >= 316574772 ORDER BY to_ip ASC LIMIT 1) as `tjv` where `from_ip` <= 316574772) union (select `user_id`, `to_ip`, `from_ip` from (select user_id, to_ip, from_ip FROM user_access_journal_volume_corporate WHERE to_ip >= 316574772 ORDER BY to_ip ASC LIMIT 1) as `tjv` where `from_ip` <= 316574772) union (select `user_id`, `to_ip`, `from_ip` from (select user_id, to_ip, from_ip FROM user_access_journal_volume_token WHERE to_ip >= 316574772 ORDER BY to_ip ASC LIMIT 1) as `tjv` where `from_ip` <= 316574772) union (select `user_id`, `to_ip`, `from_ip` from (select user_id, to_ip, from_ip FROM user_access_ebook_volume_trail WHERE to_ip >= 316574772 ORDER BY to_ip ASC LIMIT 1) as `tjv` where `from_ip` <= 316574772) union (select `user_id`, `to_ip`, `from_ip` from (select user_id, to_ip, from_ip FROM user_access_ebook_volume_corporate WHERE to_ip >= 316574772 ORDER BY to_ip ASC LIMIT 1) as `tjv` where `from_ip` <= 316574772) union (select `user_id`, `to_ip`, `from_ip` from (select user_id, to_ip, from_ip FROM user_access_ebook_volume_token WHERE to_ip >= 316574772 ORDER BY to_ip ASC LIMIT 1) as `tjv` where `from_ip` <= 316574772) union (select `user_id`, `to_ip`, `from_ip` from (select user_id, to_ip, from_ip FROM user_access_issue_trail WHERE to_ip >= 316574772 ORDER BY to_ip ASC LIMIT 1) as `tjv` where `from_ip` <= 316574772) union (select `user_id`, `to_ip`, `from_ip` from (select user_id, to_ip, from_ip FROM user_access_issue_corporate WHERE to_ip >= 316574772 ORDER BY to_ip ASC LIMIT 1) as `tjv` where `from_ip` <= 316574772) union (select `user_id`, `to_ip`, `from_ip` from (select user_id, to_ip, from_ip FROM user_access_issue_token WHERE to_ip >= 316574772 ORDER BY to_ip ASC LIMIT 1) as `tjv` where `from_ip` <= 316574772) union (select `user_id`, `to_ip`, `from_ip` from (select user_id, to_ip, from_ip FROM user_access_article_trail WHERE to_ip >= 316574772 ORDER BY to_ip ASC LIMIT 1) as `tjv` where `from_ip` <= 316574772) union (select `user_id`, `to_ip`, `from_ip` from (select user_id, to_ip, from_ip FROM user_access_article_corporate WHERE to_ip >= 316574772 ORDER BY to_ip ASC LIMIT 1) as `tjv` where `from_ip` <= 316574772) union (select `user_id`, `to_ip`, `from_ip` from (select user_id, to_ip, from_ip FROM user_access_article_token WHERE to_ip >= 316574772 ORDER BY to_ip ASC LIMIT 1) as `tjv` where `from_ip` <= 316574772) union (select `user_id`, `to_ip`, `from_ip` from (select user_id, to_ip, from_ip FROM user_access_chapter_trail WHERE to_ip >= 316574772 ORDER BY to_ip ASC LIMIT 1) as `tjv` where `from_ip` <= 316574772) union (select `user_id`, `to_ip`, `from_ip` from (select user_id, to_ip, from_ip FROM user_access_chapter_corporate WHERE to_ip >= 316574772 ORDER BY to_ip ASC LIMIT 1) as `tjv` where `from_ip` <= 316574772) union (select `user_id`, `to_ip`, `from_ip` from (select user_id, to_ip, from_ip FROM user_access_chapter_token WHERE to_ip >= 316574772 ORDER BY to_ip ASC LIMIT 1) as `tjv` where `from_ip` <= 316574772) union (select `user_id`, `to_ip`, `from_ip` from (select user_id, to_ip, from_ip FROM user_access_disease_corporate WHERE to_ip >= 316574772 ORDER BY to_ip ASC LIMIT 1) as `tjv` where `from_ip` <= 316574772) limit 1
      23.38msalphaeurekaselec_live_10_06_2022UserAccess.php#784
      Bindings
      • 0: 316574772
      • 1: 316574772
      • 2: 316574772
      • 3: 316574772
      • 4: 316574772
      • 5: 316574772
      • 6: 316574772
      • 7: 316574772
      • 8: 316574772
      • 9: 316574772
      • 10: 316574772
      • 11: 316574772
      • 12: 316574772
      • 13: 316574772
      • 14: 316574772
      • 15: 316574772
      Backtrace
      • 14. app/Models/UserAccess/UserAccess.php:784
      • 15. middleware::check_user_access:114
      • 16. vendor/laravel/framework/src/Illuminate/Pipeline/Pipeline.php:183
      • 17. vendor/laravel/framework/src/Illuminate/Routing/Middleware/SubstituteBindings.php:50
      • 18. vendor/laravel/framework/src/Illuminate/Pipeline/Pipeline.php:183
    • SELECT at.type_name, p.copyright, p.publisher_location,m.month,y.year, a.publish_on, a.nid article_nid,a.article_id, a.pmid, a.issue_id, a.title, a.abstract,a.podcast,a.altmetric_score,a.altmetric_url,a.kudos_url, a.page_count, a.first_page, a.elocator, a.last_page, i.publication_date, a.file_name, a.file_path, a.doi, a.is_epub,a.epub_type, a.volume_id, a.is_uploaded, a.editor_choice, a.is_epub, j.image_file_name, a.article_no, a.art_type AS article_type, a.supplementary_filename,a.html_filename,a.prc_filename,a.epub_filename, a.graph_abs_lg_filename, a.graph_abs_sm_filename, a.oa_image_lg_filename, a.oa_image_sm_filename, j.journal_banner,a.animated_abstract,a.erratum_in,a.erratum_for, (CASE WHEN a.issue_id =0 THEN j.epub_price ELSE j.price END) AS sell_price, j.epub_price, j.nid AS jour_nid, j.title AS journal_title, j.issn, j.eissn,j.journal_id, j.subtitle AS jour_subtitle, v.volume_id,v.volume_name AS volume, v.year_id, i.title AS issue, i.month_id ,i.type issue_type, j.subtitle,j.formerly_title, ac.subtitle AS epub_title,a.crossmark_enabled,a.text_mining_urls,a.license_urls,a.created, a.receivedate, a.revisedate, a.acceptdate,js.js_title FROM article a LEFT JOIN article_section ac ON a.is_epub = ac.art_sec_id LEFT JOIN journal_section js ON a.js_id = js.js_id LEFT JOIN article_type at ON a.art_type = at.art_type_id LEFT JOIN issue i ON a.issue_id = i.issue_id LEFT JOIN month m ON m.id = i.month_id LEFT JOIN volume v ON v.volume_id = a.volume_id INNER JOIN year y ON y.id = v.year_id INNER JOIN journal j ON j.journal_id = a.journal_id INNER JOIN publisher p ON p.publisher_id = j.publisher_id WHERE a.article_id=125449
      5.26msalphaeurekaselec_live_10_06_2022Article.php#408
      Backtrace
      • 11. app/Models/Article.php:408
      • 12. app/Http/Controllers/ArticleController.php:2515
      • 13. app/Http/Controllers/ArticleController.php:2035
      • 14. vendor/laravel/framework/src/Illuminate/Routing/Controller.php:54
      • 15. vendor/laravel/framework/src/Illuminate/Routing/ControllerDispatcher.php:43
    • select * from `journal` where `journal_id` = 56 limit 1
      1.63msalphaeurekaselec_live_10_06_2022Journal.php#64
      Bindings
      • 0: 56
      Backtrace
      • 14. app/Models/Journal.php:64
      • 15. app/Http/Controllers/ArticleController.php:2516
      • 16. app/Http/Controllers/ArticleController.php:2035
      • 17. vendor/laravel/framework/src/Illuminate/Routing/Controller.php:54
      • 18. vendor/laravel/framework/src/Illuminate/Routing/ControllerDispatcher.php:43
    • select count(*) as aggregate from (select j.nid as journal_nid,j.flyer_link,j.title ,j.issn,j.eissn,j.keyword, j.journal_id as journal_id, j.subtitle, j.image_file_name,j.description,j.journal_insight_url,j.doi from `subject_journal` as `sj` inner join `journal` as `j` on `j`.`journal_id` = `sj`.`journal_id` where j.journal_status=1 and subject_id IN (SELECT subject_id FROM subject_journal WHERE journal_id=56) and sj.journal_id!=56 group by `j`.`nid`) as `aggregate_table`
      1.61msalphaeurekaselec_live_10_06_2022Subject.php#200
      Backtrace
      • 16. app/Models/Subject.php:200
      • 17. app/Http/Controllers/ArticleController.php:2517
      • 18. app/Http/Controllers/ArticleController.php:2035
      • 19. vendor/laravel/framework/src/Illuminate/Routing/Controller.php:54
      • 20. vendor/laravel/framework/src/Illuminate/Routing/ControllerDispatcher.php:43
    • select j.nid as journal_nid,j.flyer_link,j.title ,j.issn,j.eissn,j.keyword, j.journal_id as journal_id, j.subtitle, j.image_file_name,j.description,j.journal_insight_url,j.doi from `subject_journal` as `sj` inner join `journal` as `j` on `j`.`journal_id` = `sj`.`journal_id` where j.journal_status=1 and subject_id IN (SELECT subject_id FROM subject_journal WHERE journal_id=56) and sj.journal_id!=56 group by `j`.`nid` order by `j`.`journal_id` asc limit 10 offset 0
      1.36msalphaeurekaselec_live_10_06_2022Subject.php#200
      Backtrace
      • 14. app/Models/Subject.php:200
      • 15. app/Http/Controllers/ArticleController.php:2517
      • 16. app/Http/Controllers/ArticleController.php:2035
      • 17. vendor/laravel/framework/src/Illuminate/Routing/Controller.php:54
      • 18. vendor/laravel/framework/src/Illuminate/Routing/ControllerDispatcher.php:43
    • select count(*) as aggregate from (select v.nid as volume_id,e.nid,e.title,v.issn,v.eissn,v.isbn,v.eisbn,e.ebook_id, v.image_file_name,v.file_path,v.flyer_link,v.ebook_volume_id, v.volume_name,v.doi,v.year_id,v.introduction from `subject_ebook` as `se` inner join `ebook` as `e` on `e`.`ebook_id` = `se`.`ebook_id` inner join `ebook_volume` as `v` on `v`.`ebook_id` = `se`.`ebook_id` inner join `year` as `y` on `y`.`id` = `v`.`year_id` where subject_id IN (SELECT subject_id FROM subject_journal WHERE journal_id=56) and v.ebook_status='1' and y.year > 2020 group by `v`.`nid`) as `aggregate_table`
      25.3msalphaeurekaselec_live_10_06_2022Subject.php#220
      Backtrace
      • 16. app/Models/Subject.php:220
      • 17. app/Http/Controllers/ArticleController.php:2518
      • 18. app/Http/Controllers/ArticleController.php:2035
      • 19. vendor/laravel/framework/src/Illuminate/Routing/Controller.php:54
      • 20. vendor/laravel/framework/src/Illuminate/Routing/ControllerDispatcher.php:43
    • select v.nid as volume_id,e.nid,e.title,v.issn,v.eissn,v.isbn,v.eisbn,e.ebook_id, v.image_file_name,v.file_path,v.flyer_link,v.ebook_volume_id, v.volume_name,v.doi,v.year_id,v.introduction from `subject_ebook` as `se` inner join `ebook` as `e` on `e`.`ebook_id` = `se`.`ebook_id` inner join `ebook_volume` as `v` on `v`.`ebook_id` = `se`.`ebook_id` inner join `year` as `y` on `y`.`id` = `v`.`year_id` where subject_id IN (SELECT subject_id FROM subject_journal WHERE journal_id=56) and v.ebook_status='1' and y.year > 2020 group by `v`.`nid` order by `v`.`ebook_volume_id` desc limit 10 offset 0
      30.66msalphaeurekaselec_live_10_06_2022Subject.php#220
      Backtrace
      • 14. app/Models/Subject.php:220
      • 15. app/Http/Controllers/ArticleController.php:2518
      • 16. app/Http/Controllers/ArticleController.php:2035
      • 17. vendor/laravel/framework/src/Illuminate/Routing/Controller.php:54
      • 18. vendor/laravel/framework/src/Illuminate/Routing/ControllerDispatcher.php:43
    • select * from `keywords` where `article_id` = '125449'
      21.94msalphaeurekaselec_live_10_06_2022Keywords.php#43
      Bindings
      • 0: 125449
      Backtrace
      • 13. app/Models/Keywords.php:43
      • 14. app/Http/Controllers/ArticleController.php:2519
      • 15. app/Http/Controllers/ArticleController.php:2035
      • 16. vendor/laravel/framework/src/Illuminate/Routing/Controller.php:54
      • 17. vendor/laravel/framework/src/Illuminate/Routing/ControllerDispatcher.php:43
    • select * from `article_citation` where `article_id` = '125449'
      67.75msalphaeurekaselec_live_10_06_2022Article.php#1570
      Bindings
      • 0: 125449
      Backtrace
      • 13. app/Models/Article.php:1570
      • 14. app/Http/Controllers/ArticleController.php:2520
      • 15. app/Http/Controllers/ArticleController.php:2035
      • 16. vendor/laravel/framework/src/Illuminate/Routing/Controller.php:54
      • 17. vendor/laravel/framework/src/Illuminate/Routing/ControllerDispatcher.php:43
    • select CONCAT_WS(' ',au.first_name, ' ', ifnull(au.initials,''), ' ', au.last_name) as authors, CONCAT(au.last_name, IFNULL(CONCAT(' ', au.initials), ''), ' ', au.first_name) AS authorsRIS, CONCAT_WS(' ',au.last_name, ' ', ifnull(au.initials,''), ' ', au.first_name) as authorsCiteAs, CONCAT_WS(' ',au.first_name, IFNULL(CONCAT(' ', au.initials), ''), IFNULL(CONCAT(' ', au.last_name), '')) as authorsmodal , `au`.*, `af`.`ror_id`, `af`.`institution`, `af`.`department`, `af`.`country`, `af`.`city`, `af`.`address`, (GROUP_CONCAT(TRIM(BOTH ', ' FROM CONCAT(ifnull(concat(af.institution,','),''), ifnull(concat(af.department,','),''), ifnull(concat(af.address,','),''), ifnull(concat(af.city,','),''), ifnull(concat(af.country,','),''), ifnull(concat(af.postal_code,','),''), ifnull(concat(af.phone,','),''), ifnull(concat(af.fax,','),''))) SEPARATOR '|')) as `author_affiliation`, (GROUP_CONCAT(TRIM(BOTH ', ' FROM CONCAT(ifnull(concat(af.web_view,','),''))) SEPARATOR '|')) as `web_view` from `author` as `au` left join `author_affiliation` as `af` on `au`.`author_id` = `af`.`author_id` where `au`.`article_id` = '125449' group by `au`.`author_id` order by `au`.`article_id` asc, `au`.`sequence` asc
      25.16msalphaeurekaselec_live_10_06_2022Author.php#86
      Bindings
      • 0: 125449
      Backtrace
      • 13. app/Models/Author.php:86
      • 14. app/Http/Controllers/ArticleController.php:2533
      • 15. app/Http/Controllers/ArticleController.php:2035
      • 16. vendor/laravel/framework/src/Illuminate/Routing/Controller.php:54
      • 17. vendor/laravel/framework/src/Illuminate/Routing/ControllerDispatcher.php:43
    • select `bo`.* from `bundle_offer` as `bo` where `bo`.`bundle_status` = 'A' order by `bo`.`bundle_id` desc
      430μsalphaeurekaselec_live_10_06_2022BundleOffer.php#57
      Bindings
      • 0: A
      Backtrace
      • 13. app/Models/BundleOffer.php:57
      • 14. app/Http/Controllers/ArticleController.php:2535
      • 15. app/Http/Controllers/ArticleController.php:2035
      • 16. vendor/laravel/framework/src/Illuminate/Routing/Controller.php:54
      • 17. vendor/laravel/framework/src/Illuminate/Routing/ControllerDispatcher.php:43
    • select `subtitle` from `journal` where `continues_publication_journal` = 1
      780μsalphaeurekaselec_live_10_06_2022Article.php#1960
      Bindings
      • 0: 1
      Backtrace
      • 13. app/Models/Article.php:1960
      • 14. app/Http/Controllers/ArticleController.php:2062
      • 15. vendor/laravel/framework/src/Illuminate/Routing/Controller.php:54
      • 16. vendor/laravel/framework/src/Illuminate/Routing/ControllerDispatcher.php:43
      • 17. vendor/laravel/framework/src/Illuminate/Routing/Route.php:260
    • Select j.subtitle, v.volume_id as volume_id,v.year_id,y.year as year,v.volume_name, v.total_no_of_issues, i.issue_id as issue_id,i.title as issue, i.publication_date as issue_pub_date from journal j join volume v on j.journal_id = v.journal_id join issue i on v.volume_id = i.volume_id join article a on a.issue_id = i.issue_id join year y on v.year_id = y.id where j.journal_id = 56 and i.is_uploaded = 1 order by v.volume_name+0 desc, i.title+0 desc limit 1
      101msalphaeurekaselec_live_10_06_2022Issue.php#298
      Backtrace
      • 11. app/Models/Issue.php:298
      • 12. app/Http/Controllers/ArticleController.php:2068
      • 13. vendor/laravel/framework/src/Illuminate/Routing/Controller.php:54
      • 14. vendor/laravel/framework/src/Illuminate/Routing/ControllerDispatcher.php:43
      • 15. vendor/laravel/framework/src/Illuminate/Routing/Route.php:260
    • select a.nid,a.publish_on, a.pmid,a.article_id,a.doi,j.journal_id,j.subtitle,v.volume_name,a.volume_id as volume_id, a.issue_id,a.title,first_page, last_page, page_count,abstract,ifnull(is_abstract,"y"),asec.title as article_section,at.type_name as article_type_name, a.article_id as ArticleID ,is_epub,epub_price,epub_type,a.created, y.year from `article` as `a` left join `article_section` as `asec` on `asec`.`art_sec_id` = `a`.`is_epub` left join `article_type` as `at` on `at`.`art_type_id` = `a`.`art_type` left join `journal` as `j` on `j`.`journal_id` = `a`.`journal_id` inner join `volume` as `v` on `a`.`volume_id` = `v`.`volume_id` inner join `year` as `y` on `v`.`year_id` = `y`.`id` where a.article_status != "W" and a.is_epub = 1 and a.journal_id = 56 and a.is_uploaded = 1 group by `a`.`article_id` order by `a`.`publish_on` desc
      35.79msalphaeurekaselec_live_10_06_2022Article.php#528
      Backtrace
      • 13. app/Models/Article.php:528
      • 14. app/Http/Controllers/ArticleController.php:2070
      • 15. vendor/laravel/framework/src/Illuminate/Routing/Controller.php:54
      • 16. vendor/laravel/framework/src/Illuminate/Routing/ControllerDispatcher.php:43
      • 17. vendor/laravel/framework/src/Illuminate/Routing/Route.php:260
    • select a.nid,a.publish_on, a.pmid,a.article_id,a.doi,j.journal_id,j.subtitle,v.volume_name,a.volume_id as volume_id, a.issue_id,a.title,first_page, last_page, page_count,abstract,ifnull(is_abstract,"y"),asec.title as article_section,at.type_name as article_type_name, a.article_id as ArticleID ,is_epub,epub_price,epub_type,a.created, y.year from `article` as `a` left join `article_section` as `asec` on `asec`.`art_sec_id` = `a`.`is_epub` left join `article_type` as `at` on `at`.`art_type_id` = `a`.`art_type` left join `journal` as `j` on `j`.`journal_id` = `a`.`journal_id` inner join `volume` as `v` on `a`.`volume_id` = `v`.`volume_id` inner join `year` as `y` on `v`.`year_id` = `y`.`id` where a.article_status != "W" and a.is_epub = 4 and a.journal_id = 56 and a.is_uploaded = 1 group by `a`.`article_id` order by `a`.`publish_on` desc
      45.19msalphaeurekaselec_live_10_06_2022Article.php#528
      Backtrace
      • 13. app/Models/Article.php:528
      • 14. app/Http/Controllers/ArticleController.php:2071
      • 15. vendor/laravel/framework/src/Illuminate/Routing/Controller.php:54
      • 16. vendor/laravel/framework/src/Illuminate/Routing/ControllerDispatcher.php:43
      • 17. vendor/laravel/framework/src/Illuminate/Routing/Route.php:260
    • select pdf, html, epub, prc from `article_metrics` where `article_id` = 125449 limit 1
      1.19msalphaeurekaselec_live_10_06_2022Article.php#744
      Bindings
      • 0: 125449
      Backtrace
      • 14. app/Models/Article.php:744
      • 15. app/Http/Controllers/ArticleController.php:2091
      • 16. vendor/laravel/framework/src/Illuminate/Routing/Controller.php:54
      • 17. vendor/laravel/framework/src/Illuminate/Routing/ControllerDispatcher.php:43
      • 18. vendor/laravel/framework/src/Illuminate/Routing/Route.php:260
    • select * from content_by_diseases where content_id = 125449 and content_type = 'article' order by status desc limit 1
      370μsalphaeurekaselec_live_10_06_2022Article.php#751
      Backtrace
      • 11. app/Models/Article.php:751
      • 12. app/Http/Controllers/ArticleController.php:2094
      • 13. vendor/laravel/framework/src/Illuminate/Routing/Controller.php:54
      • 14. vendor/laravel/framework/src/Illuminate/Routing/ControllerDispatcher.php:43
      • 15. vendor/laravel/framework/src/Illuminate/Routing/Route.php:260
    • select * from `node_meta` where `nid` = 207445 limit 1
      300μsalphaeurekaselec_live_10_06_2022Meta.php#30
      Bindings
      • 0: 207445
      Backtrace
      • 14. app/Models/Meta.php:30
      • 15. app/Http/Controllers/ArticleController.php:2101
      • 16. vendor/laravel/framework/src/Illuminate/Routing/Controller.php:54
      • 17. vendor/laravel/framework/src/Illuminate/Routing/ControllerDispatcher.php:43
      • 18. vendor/laravel/framework/src/Illuminate/Routing/Route.php:260
    • select `bo`.* from `bundle_offer` as `bo` where `bo`.`bundle_status` = 'A' order by `bo`.`bundle_id` desc
      360μsalphaeurekaselec_live_10_06_2022BundleOffer.php#57
      Bindings
      • 0: A
      Backtrace
      • 13. app/Models/BundleOffer.php:57
      • 14. app/Http/Controllers/ArticleController.php:2108
      • 15. vendor/laravel/framework/src/Illuminate/Routing/Controller.php:54
      • 16. vendor/laravel/framework/src/Illuminate/Routing/ControllerDispatcher.php:43
      • 17. vendor/laravel/framework/src/Illuminate/Routing/Route.php:260
    • select * from `tbl_ht_submission` as `h` where `h`.`subtitle` = 'MRMC' and (h.proposal_closing_date = 0 OR TO_DAYS(FROM_UNIXTIME(h.proposal_closing_date)) >= TO_DAYS(NOW())) order by `h`.`manuscript` asc
      410μsalphaeurekaselec_live_10_06_2022Article.php#2025
      Bindings
      • 0: MRMC
      Backtrace
      • 13. app/Models/Article.php:2025
      • 14. app/Http/Controllers/ArticleController.php:2112
      • 15. vendor/laravel/framework/src/Illuminate/Routing/Controller.php:54
      • 16. vendor/laravel/framework/src/Illuminate/Routing/ControllerDispatcher.php:43
      • 17. vendor/laravel/framework/src/Illuminate/Routing/Route.php:260
    • select count(*) as total_count, content_type_access_id as access_type from journal_access where content_type_id = '125449' and content_type = 'a' and ( (from_date <= CURDATE() and to_date >= CURDATE() and perpetual= 0) or (from_date is null and to_date is null and perpetual= 1) )
      620μsalphaeurekaselec_live_10_06_2022ContentAccess.php#647
      Backtrace
      • 11. app/Models/ContentAccess.php:647
      • 12. app/Http/Controllers/ArticleController.php:2186
      • 13. vendor/laravel/framework/src/Illuminate/Routing/Controller.php:54
      • 14. vendor/laravel/framework/src/Illuminate/Routing/ControllerDispatcher.php:43
      • 15. vendor/laravel/framework/src/Illuminate/Routing/Route.php:260
    • select * from `article` where `first_page` < '633' and is_uploaded = 1 and issue_id = 12242 order by cast(first_page as SIGNED) desc limit 1
      660μsalphaeurekaselec_live_10_06_2022Article.php#1819
      Bindings
      • 0: 633
      Backtrace
      • 14. app/Models/Article.php:1819
      • 15. app/Http/Controllers/ArticleController.php:2470
      • 16. vendor/laravel/framework/src/Illuminate/Routing/Controller.php:54
      • 17. vendor/laravel/framework/src/Illuminate/Routing/ControllerDispatcher.php:43
      • 18. vendor/laravel/framework/src/Illuminate/Routing/Route.php:260
    • select * from `article` where `last_page` > '650' and is_uploaded = 1 and issue_id = 12242 order by cast(first_page as SIGNED) asc limit 1
      570μsalphaeurekaselec_live_10_06_2022Article.php#1831
      Bindings
      • 0: 650
      Backtrace
      • 14. app/Models/Article.php:1831
      • 15. app/Http/Controllers/ArticleController.php:2472
      • 16. vendor/laravel/framework/src/Illuminate/Routing/Controller.php:54
      • 17. vendor/laravel/framework/src/Illuminate/Routing/ControllerDispatcher.php:43
      • 18. vendor/laravel/framework/src/Illuminate/Routing/Route.php:260
    • select `language_id` from `multilanguage` where `short_code` = 'en'
      290μsalphaeurekaselec_live_10_06_2022ArticleController.php#2497
      Bindings
      • 0: en
      Backtrace
      • 14. app/Http/Controllers/ArticleController.php:2497
      • 15. vendor/laravel/framework/src/Illuminate/Routing/Controller.php:54
      • 16. vendor/laravel/framework/src/Illuminate/Routing/ControllerDispatcher.php:43
      • 17. vendor/laravel/framework/src/Illuminate/Routing/Route.php:260
      • 18. vendor/laravel/framework/src/Illuminate/Routing/Route.php:206
    • select `source_lang_label`, `target_lang_label` from `multilanguage_labels` where `target_lang_id` = 1
      360μsalphaeurekaselec_live_10_06_2022MultiLanguage.php#23
      Bindings
      • 0: 1
      Backtrace
      • 13. app/Models/MultiLanguage.php:23
      • 14. app/Http/Controllers/ArticleController.php:2498
      • 15. vendor/laravel/framework/src/Illuminate/Routing/Controller.php:54
      • 16. vendor/laravel/framework/src/Illuminate/Routing/ControllerDispatcher.php:43
      • 17. vendor/laravel/framework/src/Illuminate/Routing/Route.php:260
    • select `id` from `multilanguage_article` where `article_id` = 125449 limit 1
      4msalphaeurekaselec_live_10_06_2022ArticleController.php#2506
      Bindings
      • 0: 125449
      Backtrace
      • 16. app/Http/Controllers/ArticleController.php:2506
      • 17. vendor/laravel/framework/src/Illuminate/Routing/Controller.php:54
      • 18. vendor/laravel/framework/src/Illuminate/Routing/ControllerDispatcher.php:43
      • 19. vendor/laravel/framework/src/Illuminate/Routing/Route.php:260
      • 20. vendor/laravel/framework/src/Illuminate/Routing/Route.php:206
    • select b.banner_link, b.banner_name, b.banner_script, b.banner_remarks, b.banner_file_name, b.banner_placement, bd.content_type, bd.content_id from `tbl_banner` as `b` inner join `tbl_banner_detail` as `bd` on `bd`.`banner_id` = `b`.`banner_id` inner join `users` as `u` on `u`.`id` = `b`.`updated_by` inner join `journal` as `j` on `j`.`journal_id` = `bd`.`content_id` where `b`.`banner_journal` = 1 and `bd`.`content_type` = 'J' and `bd`.`content_id` = 56 and `b`.`banner_from_date` <= 1740775219 and `b`.`banner_to_date` >= 1740775219 and `b`.`banner_status` = 'A' order by `b`.`banner_id` desc
      1.68msalphaeurekaselec_live_10_06_2022Banner.php#95
      Bindings
      • 0: 1
      • 1: J
      • 2: 56
      • 3: 1740775219
      • 4: 1740775219
      • 5: A
      Backtrace
      • 13. app/Models/Banner.php:95
      • 14. app/Http/helpers.php:404
      • 17. vendor/laravel/framework/src/Illuminate/Filesystem/Filesystem.php:124
      • 18. vendor/laravel/framework/src/Illuminate/View/Engines/PhpEngine.php:58
      • 19. vendor/laravel/framework/src/Illuminate/View/Engines/CompilerEngine.php:73
    • select b.banner_link, b.banner_name, b.banner_script, b.banner_remarks, b.banner_file_name, b.banner_placement, bd.content_type, bd.content_id from `tbl_banner` as `b` inner join `tbl_banner_detail` as `bd` on `bd`.`banner_id` = `b`.`banner_id` inner join `users` as `u` on `u`.`id` = `b`.`updated_by` inner join `journal` as `j` on `j`.`journal_id` = `bd`.`content_id` where `b`.`banner_journal` = 1 and `bd`.`content_type` = 'J' and `bd`.`content_id` = 56 and `b`.`banner_from_date` <= 1740775219 and `b`.`banner_to_date` >= 1740775219 and `b`.`banner_status` = 'A' order by `b`.`banner_id` desc
      1.64msalphaeurekaselec_live_10_06_2022Banner.php#95
      Bindings
      • 0: 1
      • 1: J
      • 2: 56
      • 3: 1740775219
      • 4: 1740775219
      • 5: A
      Backtrace
      • 13. app/Models/Banner.php:95
      • 14. app/Http/helpers.php:404
      • 17. vendor/laravel/framework/src/Illuminate/Filesystem/Filesystem.php:124
      • 18. vendor/laravel/framework/src/Illuminate/View/Engines/PhpEngine.php:58
      • 19. vendor/laravel/framework/src/Illuminate/View/Engines/CompilerEngine.php:73
    • select count(*) as aggregate from `uc_cart_products` where cart_id='e9cb2a42628df0624519d70f1abcc3f4'
      310μsalphaeurekaselec_live_10_06_2022Cart.php#271
      Backtrace
      • 15. app/Models/Cart.php:271
      • 16. view::layouts._header:291
      • 18. vendor/laravel/framework/src/Illuminate/Filesystem/Filesystem.php:124
      • 19. vendor/laravel/framework/src/Illuminate/View/Engines/PhpEngine.php:58
      • 20. vendor/laravel/framework/src/Illuminate/View/Engines/CompilerEngine.php:73
    App\Models\MultiLanguage
    1MultiLanguage.php#?
        _token
        VAW3ACTNOepU1aiukAR4k6DwO7491tP0IwgJjSqk
        uc_cart_id
        e9cb2a42628df0624519d70f1abcc3f4
        _previous
        array:1 [ "url" => "http://alpha.eurekaselect.com/article/125449" ]
        _flash
        array:2 [ "old" => [] "new" => [] ]
        PHPDEBUGBAR_STACK_DATA
        []
        path_info
        /article/125449
        status_code
        200
        
        status_text
        OK
        format
        html
        content_type
        text/html; charset=UTF-8
        request_query
        []
        
        request_request
        []
        
        request_headers
        0 of 0
        array:8 [ "accept-encoding" => array:1 [ 0 => "gzip, deflate" ] "accept" => array:1 [ 0 => "text/html,application/xhtml+xml,application/xml;q=0.9,image/avif,image/webp,image/apng,*/*;q=0.8,application/signed-exchange;v=b3;q=0.7" ] "user-agent" => array:1 [ 0 => "Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)" ] "upgrade-insecure-requests" => array:1 [ 0 => "1" ] "cache-control" => array:1 [ 0 => "no-cache" ] "pragma" => array:1 [ 0 => "no-cache" ] "connection" => array:1 [ 0 => "keep-alive" ] "host" => array:1 [ 0 => "alpha.eurekaselect.com" ] ]
        request_cookies
        []
        
        response_headers
        0 of 0
        array:5 [ "content-type" => array:1 [ 0 => "text/html; charset=UTF-8" ] "cache-control" => array:1 [ 0 => "no-cache, private" ] "date" => array:1 [ 0 => "Fri, 28 Feb 2025 20:40:19 GMT" ] "set-cookie" => array:2 [ 0 => "XSRF-TOKEN=eyJpdiI6IiswZWFyQ1pWbEQ1cHYrYkxrZWV1VGc9PSIsInZhbHVlIjoiY0RrWWtEMTh4elgwY013TTl6eStxejJOUnc0YlBKaWFMbGVSdzlob3pvRkJkY1REdHg5TTJDa3gxRzVGQUtVb1lhSTByL2tLUHpDcm5NWEJoTVRGQkFtMXRRYjROZjE2NVVsNWpDRzM5SnlHL2k5M0RON3FxK1B6NHpFMHVaS3UiLCJtYWMiOiI3NjQ1NTMyYzlmM2RjMTdmNzY3NTk4MzBlNjRiOWY3Yzc2OTY2MjE3NDg2ZWRmNWYxZjljMWEzZmI4MmFkM2M2IiwidGFnIjoiIn0%3D; expires=Mon, 03 Mar 2025 08:40:19 GMT; Max-Age=216000; path=/; secure; samesite=laxXSRF-TOKEN=eyJpdiI6IiswZWFyQ1pWbEQ1cHYrYkxrZWV1VGc9PSIsInZhbHVlIjoiY0RrWWtEMTh4elgwY013TTl6eStxejJOUnc0YlBKaWFMbGVSdzlob3pvRkJkY1REdHg5TTJDa3gxRzVGQUtVb1lhSTByL" 1 => "alphaeurekaselectnet_session=eyJpdiI6IjR5YkFGbWFIYWgyelNMRldiVnBMS2c9PSIsInZhbHVlIjoiY3E4T1dTVXJPRHh2eVBsYmxqNDg5VWRWbVZvRG03dTN5TUlJOFp0NVJmYnJmWHdxcko0UysxcUh2YmI2Ry9XejhGM1RSbElqUWVqOGtoTE9ZYnoyRGZNQlRoTjg3RkFEM1NWbjZCbng4VC9YaWJmQ3NFV0dNK0ZTNklNOFc1LzEiLCJtYWMiOiI0ZGFkMjk3N2RhM2QxMjdmOTQ2ZGIyOTFlOWQzMTlhYzc2YmE0NTRjNjQxNjlmYzFmODgwYjQyMTZhNTAxZTk3IiwidGFnIjoiIn0%3D; path=/; secure; httponly; samesite=laxalphaeurekaselectnet_session=eyJpdiI6IjR5YkFGbWFIYWgyelNMRldiVnBMS2c9PSIsInZhbHVlIjoiY3E4T1dTVXJPRHh2eVBsYmxqNDg5VWRWbVZvRG03dTN5TUlJOFp0NVJmYnJmWHdxcko0UysxcUh" ] "Set-Cookie" => array:2 [ 0 => "XSRF-TOKEN=eyJpdiI6IiswZWFyQ1pWbEQ1cHYrYkxrZWV1VGc9PSIsInZhbHVlIjoiY0RrWWtEMTh4elgwY013TTl6eStxejJOUnc0YlBKaWFMbGVSdzlob3pvRkJkY1REdHg5TTJDa3gxRzVGQUtVb1lhSTByL2tLUHpDcm5NWEJoTVRGQkFtMXRRYjROZjE2NVVsNWpDRzM5SnlHL2k5M0RON3FxK1B6NHpFMHVaS3UiLCJtYWMiOiI3NjQ1NTMyYzlmM2RjMTdmNzY3NTk4MzBlNjRiOWY3Yzc2OTY2MjE3NDg2ZWRmNWYxZjljMWEzZmI4MmFkM2M2IiwidGFnIjoiIn0%3D; expires=Mon, 03-Mar-2025 08:40:19 GMT; path=/; secureXSRF-TOKEN=eyJpdiI6IiswZWFyQ1pWbEQ1cHYrYkxrZWV1VGc9PSIsInZhbHVlIjoiY0RrWWtEMTh4elgwY013TTl6eStxejJOUnc0YlBKaWFMbGVSdzlob3pvRkJkY1REdHg5TTJDa3gxRzVGQUtVb1lhSTByL" 1 => "alphaeurekaselectnet_session=eyJpdiI6IjR5YkFGbWFIYWgyelNMRldiVnBMS2c9PSIsInZhbHVlIjoiY3E4T1dTVXJPRHh2eVBsYmxqNDg5VWRWbVZvRG03dTN5TUlJOFp0NVJmYnJmWHdxcko0UysxcUh2YmI2Ry9XejhGM1RSbElqUWVqOGtoTE9ZYnoyRGZNQlRoTjg3RkFEM1NWbjZCbng4VC9YaWJmQ3NFV0dNK0ZTNklNOFc1LzEiLCJtYWMiOiI0ZGFkMjk3N2RhM2QxMjdmOTQ2ZGIyOTFlOWQzMTlhYzc2YmE0NTRjNjQxNjlmYzFmODgwYjQyMTZhNTAxZTk3IiwidGFnIjoiIn0%3D; path=/; secure; httponlyalphaeurekaselectnet_session=eyJpdiI6IjR5YkFGbWFIYWgyelNMRldiVnBMS2c9PSIsInZhbHVlIjoiY3E4T1dTVXJPRHh2eVBsYmxqNDg5VWRWbVZvRG03dTN5TUlJOFp0NVJmYnJmWHdxcko0UysxcUh" ] ]
        session_attributes
        0 of 0
        array:5 [ "_token" => "VAW3ACTNOepU1aiukAR4k6DwO7491tP0IwgJjSqk" "uc_cart_id" => "e9cb2a42628df0624519d70f1abcc3f4" "_previous" => array:1 [ "url" => "http://alpha.eurekaselect.com/article/125449" ] "_flash" => array:2 [ "old" => [] "new" => [] ] "PHPDEBUGBAR_STACK_DATA" => [] ]
        ClearShow all
        Date ↕MethodURLData
        #12025-02-28 20:40:19GET/article/125449414311